Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How Will Novel Agents Impact The HIV Market?

Executive Summary

ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research. 


Related Content

Theratechnologies Sets $118k Yearly Price For HIV Biologic Trogarzo
First Efficacy Study for Janssen's Mosaic HIV-1 Preventive Vaccine Starting
J&J's Symtuza Will Debut In Europe On Cramped HIV Market
Encouraging HIV 'Cure' Data Strengthen Abivax
Gilead's CEO Gives Glimpse Of Strategic Opportunities As HCV Sales Slide Continues
Alnylam Plays Up Patisiran As Polyneuropathy Drug Nears Filings
Pipeline Watch: Top-Line Tenapanor, Doravirine And Tofacitinib Results
ViiV’s Visibility Grows And Pressure Mounts For What Comes Next
Bristol's Sale Of HIV Pipeline To ViiV Signals Tightened Focus
ASH 2014: Mixed results for PD-1, CAR-T in blood cancers


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts